For further processing into medical devices, IVD and pharmaceutical products only. Others N1-Methyl-Pseudo-UTP GMP Grade AOF N1-Methyl-Pseudo-UTP, GMP Grade, AOF 102 1584029687338397 Warranty LimitationIt is the sole responsibility of the customer to determine the suitability of all raw materials, products and components in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements. Roche makes no representations or warranties of any kind regarding the Product, express or implied, other than those expressly set forth in the terms and conditions of sale (if any), and disclaims all implied or statutory warranties including warranty of merchantability and fitness for a particular purpose. PID00001044 sodium salt, 100 mM, solution 10 490 896 103 10490896103 N1-Me-psUTP, pH8.3, GMP Grade, AOF,V2 N1-Me-psUTP, pH8.3, GMP Grade, AOF,V2 Reagents, kits 100 mL Not Available CustomBiotech product. Please contact your local representative. Will be supplied as "N1-Me-psUTP, pH8.3, GMP Grade, AOF, V2". Unit of measure is "mL". 1428903-59-6 (free acid) en Appearance: Clear, colorless solution pH value: 8.1–8.5 N1-Methyl-UTP (A271; pH 7.0 ε= 8.9 [L x mmol–1 x cm–1]): 95-105 mmol/L N1-Methyl-UTP (HPLC): ≥ 98.5 area% Identity (HPLC-MS): Corresponds DNases/RNases: Negative Nicking activity: Negative Functional transcription assay: Corresponds to specification Proteases: Not detectable Exonucleases: Not detectable Endotoxins: ≤ 2 EU/mL Bioburden: ≤ 5 CFU/mL Heavy metals (Ni, Co, V): ≤ 10 ppm Stability: At –15 to –25°C within specification range for 24 months. en Modified UTP for the use in mRNA synthesis. en This modified UTP can replace UTP in in-vitro-transcription reactions, e.g. for manufacturing mRNA therapeutics and vaccines. This RNA modification provides enhanced protein expression and reduced unwanted immunogenicity against the mRNA molecule itself. Its efficacy has been proven by its use in COVID-19 vaccines. en

A clean start in mRNA synthesis

Modified ribonucleotides enhance the expression and reduce the immunogenicity of mRNA. They are key to the success of therapeutic or vaccine mRNA.

Partially or completely replace UTP with this modified UTP to enhance the performance of modified mRNA. A fit-for-purpose reagent to manufacture mRNA for therapeutics and vaccines, Roche CustomBiotech N1-Methyl-Pseudo-UTP provides the performance, quality, and scale you need.

We have designed our manufacturing process from the master cell bank to final QC-release to exclude or minimize potential contaminants, thereby reducing overall process risk and simplifying procedures for regulatory approval.

rdoe_persona_userprofile

rdoe_persona_select_up

N¹-Methyl-Pseudo-UTP, GMP Grade, AOF

A clean start in mRNA synthesis

Ordering Information

Technical documents

Contact us

rdoe_persona_userprofile

rdoe_persona_select_up

N1-Methyl-Pseudo-UTP, GMP Grade, AOF

A clean start in mRNA synthesis

Related pages

Downloads

Ordering Information

Technical documents

Contact us

N¹-Methyl-Pseudo-UTP, GMP Grade, AOF